Anti-GRID2IP monoclonal antibody

Pre-made anti-GRID2IP monoclonal antibody(mab)-benchmark antibody for ELISA, affinity binding assay, drug discovery and mechanism of action (MOA) research

Target products collectionGo to GRID2IP/GRID2IP products collection >>
(antibodies, antigen, VLP, mRNA, ORF viral vector, etc)


Product information

Catalog No.Product NameSpecies Reactivity
GM-Tg-hg-IP2532-Ab-1/ GM-Tg-hg-IP2532-Ab-2Anti-Human GRID2IP monoclonal antibodyHuman
GM-Tg-rg-IP2532-Ab-1/ GM-Tg-rg-IP2532-Ab-2Anti-Rat GRID2IP monoclonal antibodyRat
GM-Tg-mg-IP2532-Ab-1/ GM-Tg-mg-IP2532-Ab-2Anti-Mouse GRID2IP monoclonal antibodyMouse
GM-Tg-cynog-IP2532-Ab-1/ GM-Tg-cynog-IP2532-Ab-2Anti-Cynomolgus/ Rhesus macaque GRID2IP monoclonal antibodyCynomolgus/ Rhesus macaque
GM-Tg-felg-IP2532-Ab-1/ GM-Tg-felg-IP2532-Ab-2Anti-Feline GRID2IP monoclonal antibodyFeline
GM-Tg-cang-IP2532-Ab-1/ GM-Tg-cang-IP2532-Ab-2Anti-Canine GRID2IP monoclonal antibodyCanine
GM-Tg-bovg-IP2532-Ab-1/ GM-Tg-bovg-IP2532-Ab-2Anti-Bovine GRID2IP monoclonal antibodyBovine
GM-Tg-equg-IP2532-Ab-1/ GM-Tg-equg-IP2532-Ab-2Anti-Equine GRID2IP monoclonal antibodyEquine

Size: 1mg | 10mg | 100mg



Product Description

Catalog No.GM-Tg-hg-IP2532-Ab-1/ GM-Tg-hg-IP2532-Ab-2; GM-Tg-rg-IP2532-Ab-1/ GM-Tg-rg-IP2532-Ab-2;
GM-Tg-mg-IP2532-Ab-1/ GM-Tg-mg-IP2532-Ab-2; GM-Tg-cynog-IP2532-Ab-1/ GM-Tg-cynog-IP2532-Ab-2;
GM-Tg-felg-IP2532-Ab-1/ GM-Tg-felg-IP2532-Ab-2; GM-Tg-cang-IP2532-Ab-1/ GM-Tg-cang-IP2532-Ab-2;
GM-Tg-bovg-IP2532-Ab-1/ GM-Tg-bovg-IP2532-Ab-2; GM-Tg-equg-IP2532-Ab-1/ GM-Tg-equg-IP2532-Ab-2
Products NameAnti-GRID2IP monoclonal antibody
Formatmab
Target NameGRID2IP
Protein Sub-locationIntrocelluar Protein
Category of antibody
Derivation (species)Mouse
CH1+2+3 Isotype
(Receptor identification)
IgG
Type of Light Chain (VD-LC)N/A
Expression platformMammalian Expression
Bioactivity validationBinding affinity is validated by ELISA with recombinant soluble protein antigen. The potency in neutralizing, inhibiting or blocking of the target protein is not detected.
TagFc
Products descriptionPre-made anti-GRID2IP monoclonal antibody(mab) is expressed by mammalian cell line as a benchmark antibody for cell culture, ELISA or other affinity binding assay or functional assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic)
Purity Purity: ≥95% (SDS-PAGE)
Application Biological drug disovery including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.
Formulation & Reconstitution Lyophilized from GM's Protein Stability Buffer2 (PSB2,Confidential Ingredients) or PBS (pH7.4);
For PSB2, reconstituted with 0.9% sodium chloride;
For PBS, reconstituted with ddH2O.
Storage Store at -20℃ to -80℃ under sterile conditions. Avoid repeated freeze-thaw cycles.

Reference




    Data / case study


    Click to get more Data / Case study about the product.



    Associated products


    CategoryCat No.Products Name
    Target AntigenGM-Tg-g-IP2532-Ag-1Recombinant multi-species GRD2I/ GRID2IP/ DELPHILIN protein


    Target information

    Target IDGM-IP2532
    Target NameGRID2IP
    Gene ID392862,170935,288484,704557,609131,101100528,518088,100061666
    Gene Symbol and SynonymsDELPHILIN,GRID2IP
    Uniprot AccessionA4D2P6
    Uniprot Entry NameGRD2I_HUMAN
    Protein Sub-locationIntrocelluar Protein
    Category
    DiseaseN/A
    Gene EnsemblENSG00000215045
    Target ClassificationN/A

    The target: GRID2IP, gene name: GRID2IP, also named as DELPHILIN. Glutamate receptor delta-2 (GRID2; MIM 602368) is predominantly expressed at parallel fiber-Purkinje cell postsynapses and plays crucial roles in synaptogenesis and synaptic plasticity. GRID2IP1 interacts with GRID2 and may control GRID2 signaling in Purkinje cells (Matsuda et al., 2006 [PubMed 16835239]).[supplied by OMIM, Mar 2008].



    About Gmab

    GDU
    GDU



    GMab, developed by GeneMedi, constitutes an advanced library of recombinant monoclonal antibodies, each meticulously designed to target specific molecular entities. Leveraging the sophisticated capabilities of GM’s Taurus™ and LIBRA™ platforms, GMab synthesizes antibodies characterized by high binding affinity, exceptional physicochemical stability, and optimal developability profiles.

    Through expression in mammalian cell lines, GMab has been established as a paradigmatic reference antibody. It holds significance in myriad domains of biological drug discovery, encompassing cellular cultivation, innovative assay methodologies, strategic animal model systematization, in-depth pharmacokinetic & pharmacodynamic (PK/PD) modeling, and intricate mechanism of action (MOA) investigations.